La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cytosorbents Dividende

Dividende contrôle des critères 0/6

Cytosorbents does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.7%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$0.47
Prévisions de rendement du dividende à 3 ans	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de CTSO ont été stables dans le passé.

Dividende croissant: Insufficient data to determine if CTSO's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Cytosorbents Rendement des dividendes par rapport au marché

Comment le rendement du dividende de CTSO se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (CTSO)	n/a
25% du marché (US)	1.5%
25% du marché (US)	4.4%
Moyenne du secteur (Medical Equipment)	1.7%
Prévisions des analystes dans 3 ans (CTSO)	n/a

Dividende notable: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate CTSO's payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as CTSO has not reported any payouts.

Cytosorbents Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Consensus EPS estimates upgraded to US$0.31 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cytosorbents Corporation Announces Chief Financial Officer Changes

Cytosorbents Corporation to Report Q2, 2024 Results on Aug 13, 2024

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

CytoSorbents Corporation Announces Regulatory Approval of CytoSorb® in Taiwan

Cytosorbents Corporation Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union

Cytosorbents Corporation Receives Notice Regarding Nasdaq Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.64 loss per share (vs US$0.75 loss in FY 2022)

No longer forecast to breakeven

Cytosorbents Corporation to Report Q1, 2024 Results on May 09, 2024

Cytosorbents Corporation, Annual General Meeting, Jun 06, 2024

No longer forecast to breakeven

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Cytosorbents Corporation to Report Fiscal Year 2023 Results on Mar 14, 2024

Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial (Rct) Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Price target decreased by 20% to US$4.50

New minor risk - Profitability

Price target decreased by 10.0% to US$5.40

Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

New minor risk - Shareholder dilution

Cytosorbents Corporation has completed a Follow-on Equity Offering in the amount of $10.28501 million.

Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding

New minor risk - Share price stability

Consensus EPS estimates fall by 20%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Cytosorbents Corporation Announces Appointment of Kathleen Bloch as Full-Time CFO

Cytosorbents Corporation Announces Resignation of Alexander D’Amico as Chief Financial Officer, Effective August 28, 2023

CytoSorbents Corporation Completes U.S. and Canadian Star-T Pivotal Trial

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cytosorbents Corporation to Report Q2, 2023 Results on Aug 01, 2023

CytoSorbents Corporation Appoints Alexander D'Amico as Chief Financial Officer

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

New minor risk - Share price stability

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Consensus EPS estimates fall by 25%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Director exercised options to buy US$97k worth of stock.

Consensus EPS estimates fall by 34%

Full year 2022 earnings released: US$0.75 loss per share (vs US$0.57 loss in FY 2021)

Forecast breakeven date pushed back to 2025

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Cytosorbents Corporation to Report Q4, 2022 Results on Mar 09, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

Cytosorbents Corporation Appoints Irina B. Kulinets as Senior Vice President of Global Regulatory Affairs

Cytosorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal Star-T Trial as Planned Without Modifications

Consensus EPS estimates fall by 18%

Insufficient new directors

Cytosorbents Announces Pivotal Star-T Trial Reaches First Milestone with 40 Patients Enrolled

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 18%

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021)

Price target decreased to US$6.67

CytoSorbents Corporation Announces Presentation of Final Key Results from the U.S. Multicenter Cytosorb Therapy

Cytosorbents Corporation to Report Q3, 2022 Results on Nov 03, 2022

CytoSorbents Corporation Announces Retirement of Kathleen P. Bloch, Chief Financial Officer

CytoSorbents secures $4.3M contract by U.S. Department of Defense

CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey

CEO & Director recently bought US$60k worth of stock

U.S. Army Medical Research Acquisition Activity Awards CytoSorbents an Approximately $2.0 Million Contract to Support Hemodefend-Bga(Tm) Development for Life-Saving Universal Plasma

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Cytosorbents Corporation Announces Turkish Ministry of Health Grants National Reimbursement to CytoSorb(R)

CytoSorbents gets reimbursement for CytoSorb in Turkey

CytoSorbents Corporation Announces Israeli Ministry of Health Approve National Reimbursement for CytoSorb(R)

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Consensus revenue estimates fall by 13%

Price target decreased to US$8.17

Second quarter 2022 earnings: EPS and revenues miss analyst expectations